Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029710431> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3029710431 endingPage "360" @default.
- W3029710431 startingPage "357" @default.
- W3029710431 abstract "Objective To develop a BP26 recombinant BCG (rBCG-BP26) vaccine,and to observe the effects of rBCG-BP26 on CD4+,CD8+ T cells in immunized mice.Methods The recombinant shuttle vector pMV261-Ag85B-BP26 was constructed by using traditional molecular biological technology.The recombinant strains were obtained by kanamycin resistance screening and PCR identification after electroporation.Western blotting was used to detect the expression of recombinant BP26 vaccine in immunized mice.Safety experiment was carried out in three different groups:the target experiment(rBCG-BP26) group,the positive control(BCG) group and the negative control(PBS) group,15 BALB/c mice in each group.Intradermal inoculations of 100 μl rBCG-BP26 [containing 106 colony forming units(CFU)],BCG,and PBS were carried out,respectively.Signs of mice in each group were observed.After immunization for 10,20,30,and 40 days,body weight was weighed,and tail blood was collected to observe the change of peripheral blood CD4+ and CD8+ T cells by flow cytometry.Results The rBCG-BP26 was successfully constructed.The expression of BP26 protein was detected in the liquid medium and the bacteria cells.The results of safety test analysis showed that there were no significant differences in signs and body weights(F=2.468,0.331,1.520,0.739,all P＞ 0.05),between PBS group[ (19.24 ± 0.54),(21.37 ± 0.66),(22.83 ± 0.62),(25.06 ± 0.37)g],BCG group[ (19.90 ± 0.02),(21.53 ± 1.57),(21.95 ± 0.55),(24.70 ± 0.39)g]and rBCG-BP26 group[ (19.16 ± 0.55 ),(20.89 ± 0.20),(22.15 ± 0.76),(24.60 ± 0.64)g].The results of flow cytometry showed that the percentages of CD4+ T cell level were lower in BCG group(26.70％,33.07％) and rBCG-BP26 group( 13.40％,26.70％) than that of the PBS group(33.85％,29.33％) and the values of CD4+/CD8+ T cells increased in rBCG-BP26 group (0.69％,1.27％,1.57％,1.70％ ) 10,20 and 30 days after immunization.Conclusions Recombinant BCG-BP26 vaccine strain can express brucella BP26 protein efficiently.Furthermore,its virulence is mild,and it can activate CD4+,CD8+ T cells in the body.It can be used as one of candidate vaccine strain against brucellosis.Key words: Brucella; Vaccines, synthetic; BCG vaccine" @default.
- W3029710431 created "2020-06-05" @default.
- W3029710431 creator A5009958266 @default.
- W3029710431 creator A5013814771 @default.
- W3029710431 creator A5035086533 @default.
- W3029710431 date "2012-07-20" @default.
- W3029710431 modified "2023-09-23" @default.
- W3029710431 title "Construction of a recombinant BCG secreting BP26 and the effects of BP26 on CD4+ and CD8+ T cells in mice" @default.
- W3029710431 doi "https://doi.org/10.3760/cma.j.issn.1000-4955.2012.04.002" @default.
- W3029710431 hasPublicationYear "2012" @default.
- W3029710431 type Work @default.
- W3029710431 sameAs 3029710431 @default.
- W3029710431 citedByCount "0" @default.
- W3029710431 crossrefType "journal-article" @default.
- W3029710431 hasAuthorship W3029710431A5009958266 @default.
- W3029710431 hasAuthorship W3029710431A5013814771 @default.
- W3029710431 hasAuthorship W3029710431A5035086533 @default.
- W3029710431 hasConcept C104317684 @default.
- W3029710431 hasConcept C147483822 @default.
- W3029710431 hasConcept C153911025 @default.
- W3029710431 hasConcept C167672396 @default.
- W3029710431 hasConcept C186852380 @default.
- W3029710431 hasConcept C203014093 @default.
- W3029710431 hasConcept C22070199 @default.
- W3029710431 hasConcept C2778288313 @default.
- W3029710431 hasConcept C40767141 @default.
- W3029710431 hasConcept C54355233 @default.
- W3029710431 hasConcept C86803240 @default.
- W3029710431 hasConceptScore W3029710431C104317684 @default.
- W3029710431 hasConceptScore W3029710431C147483822 @default.
- W3029710431 hasConceptScore W3029710431C153911025 @default.
- W3029710431 hasConceptScore W3029710431C167672396 @default.
- W3029710431 hasConceptScore W3029710431C186852380 @default.
- W3029710431 hasConceptScore W3029710431C203014093 @default.
- W3029710431 hasConceptScore W3029710431C22070199 @default.
- W3029710431 hasConceptScore W3029710431C2778288313 @default.
- W3029710431 hasConceptScore W3029710431C40767141 @default.
- W3029710431 hasConceptScore W3029710431C54355233 @default.
- W3029710431 hasConceptScore W3029710431C86803240 @default.
- W3029710431 hasIssue "04" @default.
- W3029710431 hasLocation W30297104311 @default.
- W3029710431 hasOpenAccess W3029710431 @default.
- W3029710431 hasPrimaryLocation W30297104311 @default.
- W3029710431 hasRelatedWork W2348020497 @default.
- W3029710431 hasRelatedWork W2356365915 @default.
- W3029710431 hasRelatedWork W2359020692 @default.
- W3029710431 hasRelatedWork W2359367180 @default.
- W3029710431 hasRelatedWork W2359695079 @default.
- W3029710431 hasRelatedWork W2360077699 @default.
- W3029710431 hasRelatedWork W2362560621 @default.
- W3029710431 hasRelatedWork W2362574168 @default.
- W3029710431 hasRelatedWork W2363614624 @default.
- W3029710431 hasRelatedWork W2364194382 @default.
- W3029710431 hasRelatedWork W2371087109 @default.
- W3029710431 hasRelatedWork W2374794124 @default.
- W3029710431 hasRelatedWork W2375901527 @default.
- W3029710431 hasRelatedWork W2377471595 @default.
- W3029710431 hasRelatedWork W2378669046 @default.
- W3029710431 hasRelatedWork W2381590962 @default.
- W3029710431 hasRelatedWork W2382397540 @default.
- W3029710431 hasRelatedWork W2410950565 @default.
- W3029710431 hasRelatedWork W2753691633 @default.
- W3029710431 hasRelatedWork W3028870826 @default.
- W3029710431 hasVolume "31" @default.
- W3029710431 isParatext "false" @default.
- W3029710431 isRetracted "false" @default.
- W3029710431 magId "3029710431" @default.
- W3029710431 workType "article" @default.